Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pomaglumetad methionil

- PMLiVE

Lilly feels effects of Cymbalta competition

Revenues down by 2 per cent for fourth quarter of 2013

Sanofi reception

Sanofi sues Lilly over insulin patents

Challenges development of Lantus biosimilar

- PMLiVE

Otsuka/Lundbeck say brexpiprazole works in phase III trial

On course as successor to antipsychotic Abilify

Roche Basel Switzerland

Setback for Roche as schizophrenia candidate fails studies

 Bitopertin misses primary endpoints in two phase III trials

- PMLiVE

Lilly agrees two antibody deals

Signs agreements with Genmab and Arteaus Therapeutics

- PMLiVE

Lilly: 2014 will be “most financially challenging year”

Company still to feel worst effects of patent expiries

- PMLiVE

Disney and Lilly publish diabetes books online

Digital format for resource to help families with children who have type 1 diabetes

- PMLiVE

First Cymbalta generics approved in the US

Lilly prepares for onslaught of competition for antidepressant

- PMLiVE

Interview: Mike Hutton, Lilly

Lilly’s chief scientific officer for neurodegenerative diseases talks about his hopes for Alzheimer’s research and making the move from academia to pharma

- PMLiVE

Lilly depression drug fails late-stage trials

Will not pursue edivoxetine as an add-on treatment for depression

- PMLiVE

Survey to gauge impact of doctor-patient talks in diabetes

Lilly and Boehringer sponsor worldwide study

- PMLiVE

FDA turns down Forest/Gedeon Richter’s antipsychotic

US regulator wants more information for cariprazine

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links